在早产婴儿中,多不和脂肪酸摄入量与血氧利平因概况之间的关联:一项追溯队列研究
Hiroki Suganuma1, Naho Ikeda2, Natsuki Ohkawa2
1Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan.
JPEN. Journal of parenteral and enteral nutrition
|October 9, 2025
概括
饮食中的多不和脂肪酸 (PUFA) 对早产婴儿的氧利平因型产生影响. 更高的阿拉基酸 (AA) 和多可沙赫萨酸 (DHA) 摄入量与它们衍生氧利平的水平较低相关.
科学领域:
- 生物化学 生物化学
- 新生儿营养新生儿营养
- 脂质代谢 脂质代谢是什么
背景情况:
- 氧利平是由多不和脂肪酸 (PUFA) 衍生出的生物活性脂质媒介.
- PUFA对于婴儿发育至关重要,通过母乳或配方奶粉获得.
- 过早出生的婴儿有独特的营养需求和改变的代谢途径.
研究的目的:
- 在接受肠道PUFA养的早产婴儿中描述氧利平的概况.
- 在这个人群中调查饮食中PUFA摄入量与血氧利平水平之间的关系.
主要方法:
- 27名早产婴儿 (怀孕30-34周) 在4周内每周量化PUFA摄入量 (母乳和配方奶粉).
- 用超高性能液态染色体质谱法测量出生后第7,14,21和28天的血氧利平水平.
- 使用边际结构模型与反向概率加权分析了PUFA摄入量与氧利平素之间的关联.
主要成果:
- 观察到每周PUFA摄入量的动态变化,在第2周里,酸 (LA) 和α-酸 (ALA) 达到峰值.
- 阿拉基酸 (AA) 和多可沙赫萨酸 (DHA) 的水平分别呈现稳定和急剧上升.
- 从AA和DHA衍生的氧利平与它们的摄入量呈现出显著的逆相关性,尽管变化的幅度很小.
结论:
- 饮食中PUFA的组成会影响早产婴儿的氧利平特征.
- 在AA/DHA摄入量与其衍生氧利平之间存在负相关性,这表明存在一种调节机制.
- 这些发现强调了针对早产新生儿量身定制的PUFA营养的重要性.
相关概念视频
Overview of Lipid Metabolism
7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
Inborn Errors of Metabolism
1.1K
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Development of the Oral Microbiota
65
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
65


